Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

STYLE (NCT03449173): A Phase 2 Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines
Claudia Proto, Sara Manglaviti, Giuseppe Lo Russo, et al.
Journal of Thoracic Oncology (2023) Vol. 18, Iss. 8, pp. 1070-1081
Open Access | Times Cited: 13

Showing 13 citing articles:

Genomic landscape and molecularly informed therapy in thymic carcinoma and other advanced thymic epithelial tumors
Lino Möhrmann, Lysann Rostock, Maximilian Werner, et al.
Med (2025), pp. 100612-100612
Open Access | Times Cited: 1
Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial (NCT03921671)
Claudia Proto, M. Ganzinelli, Sara Manglaviti, et al.
Annals of Oncology (2024) Vol. 35, Iss. 9, pp. 817-826
Open Access | Times Cited: 8
Pure White Cell Aplasia, an Exceedingly Rare Complication of a Thymoma, and Immune Reconstitution Following Bone Marrow Recovery
Giby V. George, Jacqueline Uy, John L. Mariano, et al.
Hematology Reports (2025) Vol. 17, Iss. 2, pp. 14-14
Open Access
An Overview of the Use of Anti-Angiogenic Agents in the Treatment of Thymic Epithelial Tumors
Apostolos C. Agrafiotis, Lawek Berzenji, Stien Koyen, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 23, pp. 17065-17065
Open Access | Times Cited: 4
Drastic response of sunitinib after failure of Lenvatinib in patients with previously treated thymic carcinoma
Kyoichi Kaira, Hisao Imai, Hiroshi Kagamu
Lung Cancer (2024) Vol. 189, pp. 107501-107501
Closed Access | Times Cited: 1
A Re-Examination of Neoadjuvant Therapy for Thymic Tumors: A Long and Winding Road
Fenghao Yu, Zhitao Gu, Xuefei Zhang, et al.
Cancers (2024) Vol. 16, Iss. 9, pp. 1680-1680
Open Access | Times Cited: 1
Insights into molecular aspects and targeted therapy of thymic carcinoma: a narrative review
Tadashi Sakane, Hiroshi Haneda, Katsuhiro Okuda
Mediastinum (2024) Vol. 8, pp. 36-36
Open Access | Times Cited: 1
A disproportionality analysis of sunitinib in the FDA adverse event reporting system (FAERS).
Wen‐Bin Zou, Yang Han, Xi Yu, et al.
Heliyon (2024), pp. e37543-e37543
Open Access | Times Cited: 1
Thymic malignancies: role of immunotherapy and novel approaches
Barbara Kiesewetter, Philipp Melhorn, Thorsten Fuereder
Current Opinion in Oncology (2024)
Closed Access | Times Cited: 1
Small molecule multitarget antiangiogenic inhibitor treatments for advanced thymic epithelial tumors: A retrospective study
W.B. Shen, Ying Jin, Ying Yu, et al.
Thoracic Cancer (2023) Vol. 15, Iss. 2, pp. 122-130
Open Access | Times Cited: 2
Evolving treatment landscape in thymic epithelial tumors: From mechanism to therapy
Yehao Yang, Ying Yu, Yun Fan, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024) Vol. 1879, Iss. 5, pp. 189145-189145
Open Access
Role of ZNF334 in cervical cancer: implications for EMT reversal and tumor suppression
Qian Li, Xiangyi Zhou, Jiayi Xiao, et al.
Medical Oncology (2024) Vol. 41, Iss. 8
Closed Access
Molecular and Functional Key Features and Oncogenic Drivers in Thymic Carcinomas
Serena Barachini, Eleonora Pardini, Irene Sofia Burzi, et al.
Cancers (2023) Vol. 16, Iss. 1, pp. 166-166
Open Access
Page 1

Scroll to top